Physician profile
Munir Javed
NPI 1568543130
$1,315.84
in general payments reported to CMS, 2019-2025
15 companies · $142 in 2025
The $142 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $752 · 2020: $81.27 · 2021: $125 · 2024: $216 · 2025: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $358.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $358.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $199.46 | 2019-2021 | |
| Amgen INC. | $190.76 | 2019-2020 | |
| Novo Nordisk INC | $181.25 | 2019-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $151.77 | 2019-2020 | |
| Glaxosmithkline, LLC. | $145.74 | 2019-2024 | Arexvy |
| Exact Sciences Corporation | $125.77 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $72.96 | 2019 | |
| Merck Sharp & Dohme LLC | $47.01 | 2019 | |
| Mylan Specialty L.P. | $42.90 | 2019 | |
| Sanofi Pasteur INC. | $38.26 | 2019 | |
| Lundbeck LLC | $27.47 | 2025 | Vyepti |
| Dynavax Technologies Corporation | $25.22 | 2024 | Heplisav-B |
| Amarin Pharma, INC. | $23.07 | 2020 | |
| Myriad Genetic Laboratories, INC. | $22.96 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $21.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Munir Javed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.